This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coskun, T. Articles by Kharitonenkov, A. Search for Related Content PubMed PubMed Citation Articles by Coskun, T. Articles by Kharitonenkov, A.

Fibroblast Growth Factor 21 Corrects Obesity in Mice

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285

Address all correspondence and requests for reprints to: Alexei Kharitonenkov, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285. E-mail: a.kharch{at}lilly.com.

Fibroblast growth factor 21 (FGF21) is a metabolic regulator that provides efficient and durable glycemic and lipid control in various animal models. However, its potential to treat obesity, a major health concern affecting over 30% of the population, has not been fully explored. Here we report that systemic administration of FGF21 for 2 wk in diet-induced obese and ob/ob mice lowered their mean body weight by 20% predominantly via a reduction in adiposity. Although no decrease in total caloric intake or effect on physical activity was observed, FGF21-treated animals exhibited increased energy expenditure, fat utilization, and lipid excretion, reduced hepatosteatosis, and ameliorated glycemia. Transcriptional and blood cytokine profiling studies revealed effects consistent with the ability of FGF21 to ameliorate insulin and leptin resistance, enhance fat oxidation and suppress de novo lipogenesis in liver as well as to activate futile cycling in adipose. Overall, these data suggest that FGF21 exhibits the therapeutic characteristics necessary for an effective treatment of obesity and fatty liver disease and provides novel insights into the metabolic determinants of these activities.

This article has been cited by other articles:

				M. K. Badman, A. R. Kennedy, A. C. Adams, P. Pissios, and E. Maratos-Flier A very low carbohydrate ketogenic diet improves glucose tolerance in ob/ob mice independently of weight loss Am J Physiol Endocrinol Metab, November 1, 2009; 297(5): E1197 - E1204. [Abstract] [Full Text] [PDF]

				M. K. Badman, A. Koester, J. S. Flier, A. Kharitonenkov, and E. Maratos-Flier Fibroblast Growth Factor 21-Deficient Mice Demonstrate Impaired Adaptation to Ketosis Endocrinology, November 1, 2009; 150(11): 4931 - 4940. [Abstract] [Full Text] [PDF]

				Y. Hotta, H. Nakamura, M. Konishi, Y. Murata, H. Takagi, S. Matsumura, K. Inoue, T. Fushiki, and N. Itoh Fibroblast Growth Factor 21 Regulates Lipolysis in White Adipose Tissue But Is Not Required for Ketogenesis and Triglyceride Clearance in Liver Endocrinology, October 1, 2009; 150(10): 4625 - 4633. [Abstract] [Full Text] [PDF]

				C. Christodoulides, P. Dyson, D. Sprecher, K. Tsintzas, and F. Karpe Circulating Fibroblast Growth Factor 21 Is Induced by Peroxisome Proliferator-Activated Receptor Agonists But Not Ketosis in Man J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3594 - 3601. [Abstract] [Full Text] [PDF]

				X. Wu, H. Ge, B. Lemon, J. Weiszmann, J. Gupte, N. Hawkins, X. Li, J. Tang, R. Lindberg, and Y. Li Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice PNAS, August 25, 2009; 106(34): 14379 - 14384. [Abstract] [Full Text] [PDF]

				H. Li, Y. Bao, A. Xu, X. Pan, J. Lu, H. Wu, H. Lu, K. Xiang, and W. Jia Serum Fibroblast Growth Factor 21 Is Associated with Adverse Lipid Profiles and {gamma}-Glutamyltransferase But Not Insulin Sensitivity in Chinese Subjects J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 2151 - 2156. [Abstract] [Full Text] [PDF]

				C. J. Nelson, J. P. Otis, and H. V. Carey A role for nuclear receptors in mammalian hibernation J. Physiol., May 1, 2009; 587(9): 1863 - 1870. [Abstract] [Full Text] [PDF]

				S. Bhatnagar, H. A. Damron, and F. B. Hillgartner Fibroblast Growth Factor-19, a Novel Factor That Inhibits Hepatic Fatty Acid Synthesis J. Biol. Chem., April 10, 2009; 284(15): 10023 - 10033. [Abstract] [Full Text] [PDF]

				U. Schibler The 2008 Pittendrigh/Aschoff Lecture: Peripheral Phase Coordination in the Mammalian Circadian Timing System J Biol Rhythms, February 1, 2009; 24(1): 3 - 15. [Abstract] [PDF]